Component

Engineered thymulin-expression plasmid delivery

3 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

Read recorded mechanisms Open recursive mind map

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What it acts on

  1. Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.

    Engineered thymulin-expression plasmid delivery → Mouse regulatory T-cell transcription factor Foxp3 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_contrast
    {"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.", "effect_direction": "increase", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Isolated lymphocyte mRNA endpoint; not direct measurement of lineage conversion.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    Engineered thymulin expression restored Foxp3 transcripts in isolated lymphocytes from allergic-airway mice.
    primary_references
    Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
    source_locator
    Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Isolated lymphocyte mRNA endpoint; not direct measurement of lineage conversion. · Recorded from source · Recorded from source

    A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
    Complete structured claim and evidence

  2. BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.

    Engineered thymulin-expression plasmid delivery → Mouse interleukin-10 / Il10 Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_contrast
    {"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.", "effect_direction": "mixed", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Mouse allergic airway model; BAL protein and isolated-lymphocyte transcript are distinct readouts.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    BAL-fluid IL-10 protein did not significantly change after engineered thymulin-expression treatment; isolated lymphocyte IL-10 transcripts were restored.
    primary_references
    Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
    source_locator
    Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Mouse allergic airway model; BAL protein and isolated-lymphocyte transcript are distinct readouts. · Recorded from source · Recorded from source

    A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
    Complete structured claim and evidence

  3. Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.

    Engineered thymulin-expression plasmid delivery → Mouse allergic airway inflammation and remodeling Recorded from sourceungraded
    Experimental context and source evidence
    evidence_access
    Full text obtained; relevant results/methods inspected. This does not assert exhaustive figure/data reanalysis.
    experimental_contrast
    {"intervention": "Thymulin-expression plasmid nanoparticles", "comparator": "Allergic disease control", "endpoint": "Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.", "effect_direction": "decrease", "combination": "single", "conditions": []} Explicit extracted experimental comparison; source-derived draft.
    experimental_model
    Established allergic airway disease in mice; engineered expression plus delivery vehicle, not ordinary native-peptide injection.
    interpretation_status
    Source-derived extraction of a fact-checked reference; access is explicit, not independent raw-data verification.
    limitations
    Interpret only within the recorded preparation, exposure and comparator. The complete source passage retains qualifications; unspecified doses/timing have not been extracted here. No clinical efficacy, nutrient deficiency or unique molecular mediation is inferred.
    plain_language
    Mucus-penetrating nanoparticle delivery of thymulin-expression plasmid after allergic disease establishment improved mouse airway inflammation, collagen/remodeling and mechanical abnormalities.
    primary_references
    Nanoparticle-based thymulin gene therapy therapeutically reverses key pathology of experimental allergic asthma | 2020 | DOI 10.1126/sciadv.aay7973 | PMID 32577505 | https://doi.org/10.1126/sciadv.aay7973
    source_locator
    Reviewed reference lines 84-84; exact primary location described in quoted passage where extracted.

    Thymulin: detailed mechanisms of action (reviewed 3 October 2026) · lines 84–84

    Original AI-assisted review of primary studies and, where relevant, official regulatory records. Access level is retained per claim. Corrections, null results and unresolved questions remain explicit. Not publisher full text or independent replication. · supports · Established allergic airway disease in mice; engineered expression plus delivery vehicle, not ordinary native-peptide injection. · Recorded from source · Recorded from source

    A 2020 study delivered a thymulin-expressing plasmid using mucus-penetrating nanoparticles after allergic disease was established in mice. Airway inflammation, collagen/remodeling and mechanical abnormalities improved. BAL-fluid IL-4 and IL-13 fell, but **IL-10 protein did not significantly change**. Isolated lymphocytes showed restored IL-10 and Foxp3 transcripts; these are different endpoints from BAL-fluid protein. TGF-β and VEGF also decreased. Record the engineered expression system and delivery vehicle, not an assumed effect of an ordinary native-peptide injection. [2020 primary study](https://doi.org/10.1126/sciadv.aay7973)
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.